Literature DB >> 21407145

Impact of universal pneumococcal vaccination on hospitalizations for pneumonia and meningitis in children in Montevideo, Uruguay.

María Catalina Pírez1, Gabriela Algorta, Alejandra Cedrés, Helena Sobrero, Adriana Varela, Gustavo Giachetto, Alicia Montano.   

Abstract

BACKGROUND: In March 2008, Uruguay included PCV7 into the routine vaccination program, in a 2 + 1 schedule for children <2 years of age. Catch-up immunization was offered to children born in 2007. Greater than 95% of children received their first and second doses. The aim of this study was to assess the effect of this strategy.
METHODS: Annual hospitalization rates (per 10,000 discharges) for community-acquired pneumonia (CAP) in children <14 years of age and pneumococcal meningitis are described prior to PCV7 vaccination (2005-2007), during the year of implementation (2008) and following vaccine introduction (2009). Data regarding age, diagnosis, vaccination status, and pneumococcal serotype were obtained from Hospital Pereira Rossell databases and vaccination records.
RESULTS: Comparison of hospitalization rates for CAP and pneumococcal-CAP (P-CAP) between prevaccine years (2005-2007) and the year after vaccination (2009) decreased significantly in all children by 56% and 48.2%, respectively. Significant reduction was observed for vaccine serotype P-CAP (serotype 14 P-CAP decreased from 26.6 to 2.5 per 10,000 discharges) in children <2 years of age. A significant reduction in pneumococcal meningitis of 59% was seen in this age group; median rates prevaccination decreased from 17 (12.2-24.9) to 7 (3-11.8) after the administration of vaccine. No vaccine failures for P-CAP or pneumococcal meningitis were seen in fully immunized children.
CONCLUSIONS: One year after PCV7 introduction into the routine vaccination schedule of Uruguay, there was a rapid and significant reduction in rates of CAP, P-CAP, and pneumococcal meningitis in children <2 years of age.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21407145     DOI: 10.1097/INF.0b013e3182152bf1

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  20 in total

1.  Decline in Child Hospitalization and Mortality After the Introduction of the 7-Valent Pneumococcal Conjugative Vaccine in Rwanda.

Authors:  Janvier Rurangwa; Nadine Rujeni
Journal:  Am J Trop Med Hyg       Date:  2016-07-18       Impact factor: 2.345

Review 2.  The potential impact of pneumococcal conjugate vaccine in Africa: Considerations and early lessons learned from the South African experience.

Authors:  Shabir A Madhi; Marta C Nunes
Journal:  Hum Vaccin Immunother       Date:  2016       Impact factor: 3.452

3.  Indirect population impact of universal PCV7 vaccination of children in a 2 + 1 schedule on the incidence of pneumonia morbidity in Kielce, Poland.

Authors:  M Patrzalek; P Gorynski; P Albrecht
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-08-16       Impact factor: 3.267

4.  Evaluating the impact of PCV-10 on invasive pneumococcal disease in Brazil: A time-series analysis.

Authors:  Ana Lucia Andrade; Ruth Minamisava; Gabriela Policena; Elier B Cristo; Carla Magda S Domingues; Maria Cristina de Cunto Brandileone; Samanta Cristine Grassi Almeida; Cristiana Maria Toscano; Ana Luiza Bierrenbach
Journal:  Hum Vaccin Immunother       Date:  2016       Impact factor: 3.452

5.  Immunogenicity following the first and second doses of 7-valent pneumococcal conjugate vaccine in HIV-infected and -uninfected infants.

Authors:  Shabir A Madhi; Alane Izu; Avye Violari; Mark F Cotton; Ravindre Panchia; Els Dobbels; Poonam Sewraj; Nadia van Niekerk; Patrick Jean-Philippe; Peter V Adrian
Journal:  Vaccine       Date:  2012-12-08       Impact factor: 3.641

6.  Laboratory surveillance of invasive pneumococcal disease in New South Wales, Australia, before and after introduction of 7-valent conjugate vaccine: reduced disease, but not antibiotic resistance rates.

Authors:  S Oftadeh; H F Gidding; G L Gilbert
Journal:  Epidemiol Infect       Date:  2012-09-25       Impact factor: 4.434

Review 7.  Pneumonia in low and middle income countries: progress and challenges.

Authors:  H J Zar; S A Madhi; S J Aston; S B Gordon
Journal:  Thorax       Date:  2013-08-16       Impact factor: 9.139

8.  Decrease in Hospitalizations for Pneumonia in Children under Five Years of Age in an Indian Reservation in Panama after the Introduction of the Heptavalent Pneumococcal Conjugate Vaccine (PCV7).

Authors:  Javier Nieto Guevara; Carlos Daza; Rebecca Smith
Journal:  Int J Pediatr       Date:  2013-05-09

9.  Impact of Pneumococcal Conjugate Vaccine Administration in Pediatric Older Age Groups in Low and Middle Income Countries: A Systematic Review.

Authors:  Kimberly Bonner; Emily Welch; Kate Elder; Jennifer Cohn
Journal:  PLoS One       Date:  2015-09-02       Impact factor: 3.240

10.  Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: A double-blind randomized controlled trial.

Authors:  Miguel W Tregnaghi; Xavier Sáez-Llorens; Pio López; Hector Abate; Enrique Smith; Adriana Pósleman; Arlene Calvo; Digna Wong; Carlos Cortes-Barbosa; Ana Ceballos; Marcelo Tregnaghi; Alexandra Sierra; Mirna Rodriguez; Marisol Troitiño; Carlos Carabajal; Andrea Falaschi; Ana Leandro; Maria Mercedes Castrejón; Alejandro Lepetic; Patricia Lommel; William P Hausdorff; Dorota Borys; Javier Ruiz Guiñazú; Eduardo Ortega-Barría; Juan P Yarzábal; Lode Schuerman
Journal:  PLoS Med       Date:  2014-06-03       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.